With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3.

Nanjing Mingde New Drug Research Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation.

AZM-152 works by blocking the NLRP3 inflammasome, a crucial inflammatory pathway involved in BPD and other diseases. This compound specifically targets the receptor for hyaluronan-mediated ...

Jupiter Neurosciences (JUNS) announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims ...

In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, ...